Publication Name	World Journal of Diabetes
Manuscript ID	119285
Country	Türkiye

Category	Endocrinology & Metabolism
Manuscript Type	Minireviews
Article Title	Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in management of diabetic metabolic dysfunction-associated steatotic liver disease
Manuscript Source	Invited Manuscript
All Author List	Tuba Taslamacioglu Duman, Yagmur Ucar, Elif Sude Turkoglu, Burcin Meryem Atak Tel, Satilmis Bilgin and Gulali Aktas
Funding Agency and Grant Number
Corresponding Author	Gulali Aktas, Chief Physician, Professor, Department of Internal Medicine, Bolu Abant Izzet Baysal University Hospital, Golkoy, Bolu 14030, Türkiye. draliaktas@yahoo.com
Key Words	Metabolic dysfunction associated steatotic liver disease; Type 2 diabetes mellitus; Sodium-glucose co-transporter 2 inhibitor; Glucagon-like peptide-1 receptor agonist; Management
Core Tip	Metabolic dysfunction–associated steatotic liver disease is highly prevalent and closely intertwined with type 2 diabetes mellitus, sharing common pathophysiological mechanisms and therapeutic targets. Emerging evidence indicates that sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, beyond their established glycemic benefits, exert favorable effects on body weight, hepatic steatosis, and cardiometabolic risk. This minireview synthesizes current clinical and experimental data on the role of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease, highlighting their mechanisms of action, therapeutic potential, and implications for integrated management of patients with or at risk for type 2 diabetes mellitus.
Citation	Duman TT, Ucar Y, Turkoglu ES, Atak Tel BM, Bilgin S, Aktas G. Effects of sodium glucose co-transporter-2 inhibitors and glucagon like peptide-1 receptor agonists in management of diabetic metabolic dysfunction-associated steatotic liver disease. World J Diabetes 2026; In press

Received	2026-01-23 00:31
Peer-Review Started	2026-02-02 00:52
First Decision by Editorial Office Director	2026-02-26 07:20
Return for Revision	2026-02-26 07:20
Revised	2026-02-28 10:39
Publication Fee Transferred
Second Decision by Editor	2026-05-19 02:41
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-05-19 08:11
Articles in Press	2026-05-19 08:11
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com